Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Pharmacology and Therapeutics of Bronchodilators
An important step in simplifying asthma and COPD management and improving adherence with prescribed therapy is to reduce the dose frequency to the minimum necessary to maintain disease control, so the incorporation of once-daily dose administration is an important strategy to improve adherence.
β2-agonist therapy in lung disease.
- M. Cazzola, C. Page, P. Rogliani, M. Matera
- Medicine, BiologyAmerican journal of respiratory and critical care…
- 24 January 2013
β2-Agonists are effective bronchodilators due primarily to their ability to relax airway smooth muscle (ASM), and some novel once-daily β2-agonists (olodaterol, vilanterol, abediterol) are under development, mainly in combination with an inhaled corticosteroid or a long-acting antimuscarinic agent.
TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water.
A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.
β2‐adrenoceptor agonists: current and future direction
It is likely that the once‐daily dosing of a bronchodilator would be a significant convenience and probably a compliance‐enhancing advantage, leading to improved overall clinical outcomes.
Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?
Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
Clinical Pharmacokinetics of Salmeterol
The available data clearly show that at the recommended doses of salmeterol, systemic concentrations are low or even undetectable, and it has been demonstrated that the systemic effects of sal meterol are more likely to occur with higher doses, which lead to approximately proportionally increased blood concentrations.
The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD.